Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common supplement curb opioid cravings? small trial hints at possibility

NCT ID NCT05480072

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small, early-stage study tested whether a dietary supplement called palmitoylethanolamide (PEA) could help people with opioid use disorder feel less stress, craving, and pain. Twelve adults already on stable medication for opioid use took PEA or a placebo for three weeks. The goal was to see if PEA could reduce stress-triggered cravings, which might help prevent relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palmitoylethanolamide (PEA), a dietary supplement
What this could lead to
If it works, this could point toward a new, non-addictive supplement to help people with opioid use disorder manage stress and cravings.
What could go wrong
This was a very small, early-phase trial with only 12 participants. Results may not apply to everyone, and the supplement may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

12 people

The number who actually took part.

Started

Nov 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 * DSM-5 diagnosis of OUD * English speaking * Receiving either buprenorphine or methadone for treatment of opioid use disorder for at least 3 consecutive months prior to enrollment * Receiving a stable dose of buprenorphine or methadone for the duration of the study * Agreeable to abstaining from using any cannabis or CBD products two weeks prior to enrollment in the study, and for the duration of the trial * For women of childbearing potential: agreeable to use one of the following: * hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants * barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) * intrauterine device (IUD) * abstinence (no sex) Exclusion Criteria: * DSM-5 diagnosis of moderate-to-severe cannabis use disorder, alcohol use disorder, and/or psychostimulant use disorder \[medical record review and health history form\] * Active, recurrent substance use within the last 3 months that will interfere with study participation and completion of study procedures \[medical record review and health history form\] * History of psychotic, bipolar and schizoaffective disorders \[medical record review and health history form\] * Lifetime psychiatric hospitalization or suicide attempt, as assessed by the health history form * Recent history (within 2 years) of major depressive disorder \[health history form and clinical interview\] * Currently pregnant or breastfeeding (female only) \[pregnancy test/ self-reported\] * History of autoimmune or chronic inflammatory diseases \[health history form\] Current use of medications known to alter inflammatory and immune response \[health history form\] Raynaud's disease \[health history form\] * BMI \>45 * Hepatic liver enzymes greater than 3x upper normal limit * Vital signs: HR ≤60 or ≥100, SBP ≤90 or ≥160, DBP ≤50 or ≥100, RR \< 12 or \> 20 * Recent history of clinically significant medical conditions including, but not limited to, malignancy (and treatment for malignancy), HIV, immunological, endocrine (including uncontrolled diabetes or thyroid disease), renal, GI, or hematological abnormalities that are uncontrolled\* \[health history form and medical record review\]

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.